Biocarn®

Therapeutic indications

  • as substitution therapy for primary and secondary systemic carnitine deficiency.
  • as an attempted treatment of special forms of muscular dystrophy and lipid accumulation associated with primary muscle carnitine deficiency.
  • to complement the treatment of progressive Duchenne muscular dystrophy, if functioning skeletal muscle is still present.

Biocarn 1 g levocarnitine/3.3 ml syrup Therapeutic indications: As substitution therapy for primary and secondary systemic carnitine deficiency; as an attempted treatment of special forms of muscular dystrophy (muscle wasting) and lipid accumulation (build up of fats) associated with primary muscle carnitine deficiency; to complement the treatment of progressive Duchenne muscular dystrophy, if functioning skeletal muscle is still present; to compensate for levocarnitine losses resulting from dialysis in chronic haemodialysis. For the risks and adverse reactions, read the package insert and consult your doctor or pharmacist.